Expression profiling of sorafenib-resistant hepatospheres revealed CD47 as a significantly upregulated tumour-initiation marker compared with control parental HCC cells.107 CD47 knockdown or inhibition by neutralising antibodies re-sensitised the sorafenib-resistant cells to sorafenib treatment. Here, CD47 is linked to hepatocellular carcinoma.